Journal
CANADIAN JOURNAL OF CARDIOLOGY
Volume 38, Issue 1, Pages 77-84Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cjca.2021.09.021
Keywords
-
Categories
Funding
- University Hospital Foundation
- Servier Canada
- Heart and Stroke Foundation
- Heart & Stroke Chair in Cardiovascular Research
- Alberta Health Services Chair in Cardiovascular Outcomes Research
Ask authors/readers for more resources
This retrospective cohort study found that frail patients with nonvalvular atrial fibrillation (NVAF) were less likely to receive anticoagulation treatment, and if they did, they were more likely to receive warfarin instead of direct oral anticoagulants (DOACs). The introduction of DOACs increased anticoagulation rates but did not resolve the treatment disparities for frail NVAF patients.
Background: The extent to which the introduction of direct oral anticoagulants (DOACs) influenced treatment patterns in frail and nonfrail patients with nonvalvular atrial fibrillation (NVAF) is unclear. Methods: This was a retrospective cohort study of all Albertans 20 years or older who were discharged from an emergency department or hospital with a new diagnosis of NVAF between April 1, 2009, and March 31, 2019. The Hospital Frailty Risk Score was used to define frailty and the CHA(2)DS(2)-VASc and CHADS-65 scores were used to identify if anticoagulation was indicated. Results: Among 75,796 patients (median age, 75 years; 45% female) with a new diagnosis of NVAF, 17,143 (22.6%) were frail. Although guideline criteria for anticoagulation were more commonly met by frail patients than nonfrail patients (92.1% vs 74.2%, for CHA(2)DS(2)-VASc, and 96.8% vs 85.8% for CHADS-65; both P < 0.0001), frail patients were less likely to receive any anticoagulant, even after those with contraindications to anticoagulation were excluded (adjusted odds ratio, 0.61; 95% confidence interval, 0.58-0.64). After DOACs became available, anticoagulant prescribing for patients with guideline indications increased more in nonfrail patients (from 42.4% to 68.2%) than in frail patients (from 29.0% to 52.2%) and frail patients were less likely to receive a DOAC than warfarin (adjusted odds ratio, 0.66; 95% confidence interval, 0.54-0.81). Conclusions: Although they stand to potentially derive greater benefits from anticoagulation, frail patients were less likely to receive an anticoagulant and, if anticoagulated, they were more likely to receive warfarin than a DOAC. The introduction of DOACs has increased anticoagulation rates but not resolved treatment gaps for frail patients with NVAF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available